Skip to main content
Top
Published in: BMC Pediatrics 1/2020

01-12-2020 | Constipation | Case report

Severe constipation as the first clinical manifestation in multiple endocrine neoplasia type 2B: a case report and literature review

Authors: Lidan Zhang, Yan Guo, Lei Ye, Wenli Lu, Zhiya Dong, Wei Wang, Yuan Xiao

Published in: BMC Pediatrics | Issue 1/2020

Login to get access

Abstract

Background

The occurrence of multiple endocrine neoplasia type 2B (MEN2B) in Asians is very rare. In particular, patients with intractable constipation as the main clinical manifestation are even rarer. Atypical clinical manifestations are likely to lead to a diagnostic delay. In this report, we described a case of a delayed diagnosis of MEN2B, and the first clinical manifestation was intractable constipation.

Case presentation

A female teenager had suffered from intractable constipation since infancy. Because the colonoscopy and biopsy results from local hospitals did not confirm the presence of congenital megacolon, the girl had been followed up at a local clinic for a long time. The diagnosis was not confirmed until thyroid masses were found in the Pediatric Department of Shanghai Ruijin Hospital when she was 12 years old. According to our detailed evaluation, she suffered from Hirschsprung disease (HD), growth retardation, medullary thyroid carcinoma (MTC) and mucosal neuroma due to a mutation in the RET gene. Thus, the diagnosis of MEN2B was confirmed. Afterward, the girl underwent several surgeries and was still being followed up before the article was published.

Conclusion

MEN2B has atypical clinical symptoms in the early stage. Refractory constipation may be the only clinical manifestation that lasts for several years. Therefore, we recommend that early screening and gene sequencing should be performed for patients with severe constipation due to HD to determine the cause of the disease and to improve the survival outcome.
Literature
1.
go back to reference MacIntosh RB, Shivapuja PK, Krzemien MB, Lee M. Multiple endocrine neoplasia type 2B: maxillofacial significance in 5 cases. J Oral Maxillofac Surg. 2014;72(12):2498.e2491–17.CrossRef MacIntosh RB, Shivapuja PK, Krzemien MB, Lee M. Multiple endocrine neoplasia type 2B: maxillofacial significance in 5 cases. J Oral Maxillofac Surg. 2014;72(12):2498.e2491–17.CrossRef
2.
go back to reference Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.CrossRef Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.CrossRef
3.
go back to reference Vasen HF, van der Feltz M, Raue F, Kruseman AN, Koppeschaar HP, Pieters G, Seif FJ, Blum WF, Lips CJ. The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. Arch Intern Med. 1992;152(6):1250–2.CrossRef Vasen HF, van der Feltz M, Raue F, Kruseman AN, Koppeschaar HP, Pieters G, Seif FJ, Blum WF, Lips CJ. The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. Arch Intern Med. 1992;152(6):1250–2.CrossRef
4.
go back to reference Chong GC, Beahrs OH, Sizemore GW, Woolner LH. Medullary carcinoma of the thyroid gland. Cancer. 1975;35(3):695–704.CrossRef Chong GC, Beahrs OH, Sizemore GW, Woolner LH. Medullary carcinoma of the thyroid gland. Cancer. 1975;35(3):695–704.CrossRef
5.
go back to reference Camacho CP, Hoff AO, Lindsey SC, Signorini PS, Valente FO, Oliveira MN, Kunii IS, Biscolla RP, Cerutti JM, Maciel RM. Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physicians. Arq Bras Endocrinol Metabol. 2008;52(8):1393–8.CrossRef Camacho CP, Hoff AO, Lindsey SC, Signorini PS, Valente FO, Oliveira MN, Kunii IS, Biscolla RP, Cerutti JM, Maciel RM. Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physicians. Arq Bras Endocrinol Metabol. 2008;52(8):1393–8.CrossRef
6.
go back to reference Feichter S, Meier-Ruge WA, Bruder E. The histopathology of gastrointestinal motility disorders in children. Semin Pediatr Surg. 2009;18(4):206–11.CrossRef Feichter S, Meier-Ruge WA, Bruder E. The histopathology of gastrointestinal motility disorders in children. Semin Pediatr Surg. 2009;18(4):206–11.CrossRef
7.
go back to reference Leboulleux S, Travagli JP, Caillou B, Laplanche A, Bidart JM, Schlumberger M, Baudin E. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer. 2002;94(1):44–50.CrossRef Leboulleux S, Travagli JP, Caillou B, Laplanche A, Bidart JM, Schlumberger M, Baudin E. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer. 2002;94(1):44–50.CrossRef
8.
go back to reference Brauckhoff M, Gimm O, Weiss CL, Ukkat J, Sekulla C, Brauckhoff K, Thanh PN, Dralle H. Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg. 2004;28(12):1305–11.CrossRef Brauckhoff M, Gimm O, Weiss CL, Ukkat J, Sekulla C, Brauckhoff K, Thanh PN, Dralle H. Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg. 2004;28(12):1305–11.CrossRef
9.
go back to reference Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD, Berg JS, Biswas S, Bowling KM, Conlin LK, et al. Performance of ACMG-AMP variant-interpretation guidelines among nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet. 2016;99(1):247.CrossRef Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD, Berg JS, Biswas S, Bowling KM, Conlin LK, et al. Performance of ACMG-AMP variant-interpretation guidelines among nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet. 2016;99(1):247.CrossRef
10.
go back to reference King SK, Southwell BR, Hutson JM. An association of multiple endocrine neoplasia 2B, a RET mutation; constipation; and low substance P-nerve fiber density in colonic circular muscle. J Pediatr Surg. 2006;41(2):437–42.CrossRef King SK, Southwell BR, Hutson JM. An association of multiple endocrine neoplasia 2B, a RET mutation; constipation; and low substance P-nerve fiber density in colonic circular muscle. J Pediatr Surg. 2006;41(2):437–42.CrossRef
11.
go back to reference Gfroerer S, Theilen TM, Fiegel H, Harter PN, Mittelbronn M, Rolle U. Identification of intestinal ganglioneuromatosis leads to early diagnosis of MEN2B: role of rectal biopsy. J Pediatr Surg. 2017;52(7):1161–5.CrossRef Gfroerer S, Theilen TM, Fiegel H, Harter PN, Mittelbronn M, Rolle U. Identification of intestinal ganglioneuromatosis leads to early diagnosis of MEN2B: role of rectal biopsy. J Pediatr Surg. 2017;52(7):1161–5.CrossRef
12.
go back to reference Fialkowski EA, DeBenedetti MK, Moley JF, Bachrach B. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J Pediatr Surg. 2008;43(1):188–90.CrossRef Fialkowski EA, DeBenedetti MK, Moley JF, Bachrach B. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. J Pediatr Surg. 2008;43(1):188–90.CrossRef
13.
go back to reference Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol. 2010;322(1–2):2–7.CrossRef Frank-Raue K, Rondot S, Raue F. Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol. 2010;322(1–2):2–7.CrossRef
14.
go back to reference Khatami F, Tavangar SM. Multiple endocrine Neoplasia syndromes from genetic and epigenetic perspectives. Biomark Insights. 2018;13:1177271918785129.CrossRef Khatami F, Tavangar SM. Multiple endocrine Neoplasia syndromes from genetic and epigenetic perspectives. Biomark Insights. 2018;13:1177271918785129.CrossRef
15.
go back to reference Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 2013;98(8):3149–64.CrossRef Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab. 2013;98(8):3149–64.CrossRef
16.
go back to reference Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, Song P, Marathe A, Balakrishnan S, Zhu H, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid Cancer in patients with Unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18(14):3722–30.CrossRef Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, Song P, Marathe A, Balakrishnan S, Zhu H, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid Cancer in patients with Unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18(14):3722–30.CrossRef
17.
go back to reference Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–41.CrossRef Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–41.CrossRef
18.
go back to reference Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.CrossRef Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.CrossRef
19.
go back to reference Nelkin B. Recent advances in the biology and therapy of medullary thyroid carcinoma. F1000Research. 2017;6:2184. Nelkin B. Recent advances in the biology and therapy of medullary thyroid carcinoma. F1000Research. 2017;6:2184.
20.
go back to reference Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.CrossRef Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.CrossRef
21.
go back to reference Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M, Kumahara Y. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg. 1984;199(4):461–6.CrossRef Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M, Kumahara Y. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg. 1984;199(4):461–6.CrossRef
Metadata
Title
Severe constipation as the first clinical manifestation in multiple endocrine neoplasia type 2B: a case report and literature review
Authors
Lidan Zhang
Yan Guo
Lei Ye
Wenli Lu
Zhiya Dong
Wei Wang
Yuan Xiao
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2020
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-020-02224-4

Other articles of this Issue 1/2020

BMC Pediatrics 1/2020 Go to the issue